129 related articles for article (PubMed ID: 24499082)
41. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
[TBL] [Abstract][Full Text] [Related]
43. Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.
Abdullah S; Diezi M; Sung L; Dupuis LL; Geary D; Abla O
Pediatr Blood Cancer; 2008 Jul; 51(1):59-61. PubMed ID: 18240167
[TBL] [Abstract][Full Text] [Related]
44. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
46. Sevelamer reduces the efficacy of many other drugs.
Prescrire Int; 2009 Aug; 18(102):164-5. PubMed ID: 19743578
[TBL] [Abstract][Full Text] [Related]
47. An overview of regular dialysis treatment in Japan (as of 31 December 2004).
Nakai S; Wada A; Kitaoka T; Shinzato T; Nagura Y; Kikuchi K; Masakane I; Shinoda T; Yamazaki C; Sakai R; Marubayashi S; Morita O; Iseki K; Usami T; Kimata N; Suzuki K; Tabei K; Fushimi K; Miwa N; Yauchi M; Wakai K; Akiba T
Ther Apher Dial; 2006 Dec; 10(6):476-97. PubMed ID: 17199880
[TBL] [Abstract][Full Text] [Related]
48. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
[TBL] [Abstract][Full Text] [Related]
49. [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].
Ito M; Mochizuki T; Koike T; Hashimoto N; Fukazawa S; Akatsuka T; Niida Y; Tozawa S; Yasuda T; Sato M
Clin Calcium; 2005 Sep; 15 Suppl 1():11-13; discussion 13-4. PubMed ID: 16279016
[TBL] [Abstract][Full Text] [Related]
50. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
Lai B; Cervelli MJ
Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
[TBL] [Abstract][Full Text] [Related]
51. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
Kakuta T; Tanaka R; Hyodo T; Suzuki H; Kanai G; Nagaoka M; Takahashi H; Hirawa N; Oogushi Y; Miyata T; Kobayashi H; Fukagawa M; Saito A
Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
[TBL] [Abstract][Full Text] [Related]
52. Metabolic acidosis in peritoneal dialysis patients: the role of residual renal function.
Tian XK; Shan YS; Zhe XW; Cheng LT; Wang T
Blood Purif; 2005; 23(6):459-65. PubMed ID: 16244471
[TBL] [Abstract][Full Text] [Related]
53. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
[TBL] [Abstract][Full Text] [Related]
54. Sevelamer carbonate.
Barna MM; Kapoian T; O'Mara NB
Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
[TBL] [Abstract][Full Text] [Related]
55. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients.
Borràs M; Marco MP; Fernández E
Perit Dial Int; 2002; 22(6):737-8. PubMed ID: 12556084
[No Abstract] [Full Text] [Related]
56. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
[TBL] [Abstract][Full Text] [Related]
57. The deleterious effect of metabolic acidosis on nutritional status of hemodialysis patients.
Soleymanian T; Ghods A
Saudi J Kidney Dis Transpl; 2011 Nov; 22(6):1149-54. PubMed ID: 22089772
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
59. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
Fischer D; Cline K; Plone MA; Dillon M; Burke SK; Blair AT
Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
[TBL] [Abstract][Full Text] [Related]
60. Metabolic acidosis in hemodialysis patients: a study of prevalence and factors affecting intradialytic bicarbonate gain.
Sepandj F; Jindal K; Kiberd B; Hirsch D
Artif Organs; 1996 Sep; 20(9):976-80. PubMed ID: 8864017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
